

Collet-Sicard Syndrome as the Presentation of Malignant Pheochromocytoma

Jordan Y. Amar, MD, MSc¹ , Jeffrey Ruta, MD², Danielle Bazer, MD³, Anup Bhattacharya, MD⁴, and Arun S. Varadhachary, MD, PhD⁵

Keywords

cranial nerve neoplasms, cranial nerve diseases, nervous system, neoplasms, neurooncology, clinical specialty, neuroradiology, clinical specialty, brain neoplasms, nervous system neoplasms

A 51-year-old man developed progressive dysarthria. Hours after presenting, he experienced paroxysmal diaphoresis and blood pressure fluctuations (Figure 1A). Examination showed weak cough, hoarseness, flaccid dysarthria, weak left shoulder shrug, and left tongue deviation. Our findings of lower cranial neuropathies prompted brainstem and neck imaging, revealing contrast-enhancing mass in the jugular foramen (Figure 1B). His dysautonomia compelled neuroendocrine studies, which showed elevated chromagranin A (7047 ng/mL; normal <93), epinephrine (3334 µg; normal <21), and norepinephrine (1117 µg; normal 15-80). Abdominal imaging indicated a large retroperitoneal mass (Figure 1C), confirmed as a pheochromocytoma (pheo) on biopsy.

Malignant pheo is rare, accounting for 8% to 13% of catecholamine-secreting tumors; this is classically described as the “10% rule.”¹ There are sparse reports of neuraxis involvement.^{2,3} Diagnostic challenges arise, given that hyperadrenergic spells (ie, diaphoresis, tachycardia, hypertension) are nonspecific, and abdominal tumor burden can remain asymptomatic for years—as seen in our patient.^{4,5} Local tissue invasion is often the only clue.^{4,6} In our case, cranial nerve 9 to 12 involvement offered localizing value to the jugular foramen (Figure 1D), eponymously known as the Collet-Sicard syndrome (CSS).^{7,8} The differential diagnosis for CSS is broad, including tumor (eg, glomus jugulare, meningioma, schwannoma), trauma (vertebral fracture), inflammatory disorders (sarcoid, systemic lupus), infection (varicella zoster), and vascular phenomena (carotid aneurysm, venous thrombosis).^{8,9} Here, malignant pheo represented a possible unifying diagnosis between CSS and hyperadrenergic spells. This concern prompted neuroendocrine studies. Given that ~95% of malignant pheo’s are intra-abdominal in origin, elevated catecholamines should further compel abdominal imaging for both prognostication and treatment guidance.¹⁰

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

The Neurohospitalist
2020, Vol. 10(4) 320-321
© The Author(s) 2020
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/1941874420916302
journals.sagepub.com/home/NHO



Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Jordan Y. Amar, MD, MSc  <https://orcid.org/0000-0002-2455-6543>

References

1. Jimenez P, Tatsui C, Jessop A, Thosani S, et al. Treatment for malignant pheochromocytomas and paragangliomas: 5 years of progress. *Curr Oncol Rep.* 2017;19(12):83.
2. Boettcher LB, Abou-Al-Shaar H, Ravindra VM, et al. Intracranial epidural metastases of adrenal pheochromocytoma: a rare entity. *World Neurosurg.* 2018;114:235-240.
3. Liu S, Song A, Zhou X, et al. Malignant pheochromocytoma with multiple vertebral metastases causing acute incomplete paralysis during pregnancy: Literature review with one case report. *Medicine (Baltimore).* 2017;96(44):e8535.
4. Bravo EL. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. *Endocr Rev.* 1994;15(3):356-368.

¹ Department of Neurology, Washington University School of Medicine, St Louis, MO, USA

² Department of Neurology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA

³ Department of Neurology, Stony Brook University School of Medicine, Stony Brook, NY, USA

⁴ Mallinckrodt Institute of Radiology, St Louis, MO, USA

⁵ Department of Neurology, Washington University School of Medicine, St Louis, MO, USA

Corresponding Author:

Jordan Y. Amar, Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.
Email: jordan.amar@wustl.edu




Figure 1. A, Line plots of blood pressure fluctuations during the first 12 hours after initial presentation. B, Axial T1-weighted magnetic resonance image of the neck with contrast demonstrating avidly enhancing mass (outlined) within the left jugular foramen, extending medially and eroding the left aspect of the clivus. C, Coronal computed tomography of the abdomen showing large retroperitoneal soft tissue mass (arrow), likely the primary tumor, displacing loops of bowel inferiorly and medially. D, Cross-sectional schematic representation of structures passing through the jugular foramen.

5. Baguet JP, Hammer L, Mazzucco TL, et al. Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients. *Eur J Endocrinol.* 2004;150(5):681-686.
6. Hamidi O, Young WF Jr, , Iñiguez-Ariza NM, et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. *J Clin Endocrinol Metab.* 2017;102(9):3296.
7. Collet FJ. Sur un nouveau syndrome paralytique pharyngolarynge par blessure de guerre (hemiplegie glosso-laryngo-scalpo-pharyngee). *Lyon Med.* 1915;124:121-129.
8. Prashant R, Franks A. Collet-Sicard syndrome—a report and review. *Lancet Oncol.* 2003;4(6):376-377.
9. Neo S, Lee KE. Collet-Sicard syndrome: a rare but important presentation of internal jugular vein thrombosis. *Pract Neurol.* 2017;17(1):63-65.
10. Mei L, Khurana A, Al-Juhaishi T, et al. Prognostic factors of malignant pheochromocytoma and paraganglioma: a combined SEER and TCGA databases review. *Horm Metab Res.* 2019; 51(7):451-457.